Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Laureate Pharma Collaborates with Boehringer Ingelheim

  • Laureate Pharma’s clients will gain access to Boehringer Ingelheim's manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture.

    Under this preferred partnership agreement, Laureate says the firm will now offer its clients bioprocessing services that include creation and development of production cell lines using Boehringer Ingelheim’s BI HEX expression system, full-service process development and manufacture of early-stage clinical supplies at Laureate’s cGMP manufacturing facility in Princeton, NJ, and access to large-scale commercial production by Boehringer Ingelheim at its facility in Biberach, Germany.

    The companies will work together to ensure smooth transfer of manufacturing activities from Laureate to Boehringer Ingelheim, notes Robert J. Broeze, Ph.D., president and CEO of Laureate Pharma.

    This collaboration complements Laureate’s current service offerings with cell line development along with large-scale manufacturing capabilities, adds Dr. Broeze.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »